Celularity (NASDAQ:CELU) Stock Price Down 3.4% – Here’s Why

Celularity, Inc. (NASDAQ:CELU) dropped 3.4% during trading on Wednesday . The company traded as low as $0.6281 and last traded at $0.6762. 392,390 shares were traded during mid-day trading, an increase of 167% from the average daily volume of 146,970 shares. The stock had previously closed at $0.6998.

Celularity Stock Down 3.4%

The business’s 50-day simple moving average is $0.92 and its two-hundred day simple moving average is $1.17. The firm has a market capitalization of $19.58 million, a price-to-earnings ratio of -0.20 and a beta of 0.48.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.85) EPS for the quarter. The firm had revenue of $4.10 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CELU. XTX Topco Ltd grew its stake in shares of Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after buying an additional 11,057 shares in the last quarter. Perennial Investment Advisors LLC purchased a new position in Celularity during the 3rd quarter valued at about $28,000. Acadian Asset Management LLC purchased a new position in Celularity during the 1st quarter valued at about $34,000. Geode Capital Management LLC grew its position in Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after acquiring an additional 20,876 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after purchasing an additional 35,023 shares during the period. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.